MDL 3163 · United States District Court for the Eastern District of Pennsylvania
Sudden sight loss after a GLP-1 drug? Seek eye care right away.
Updated 13 sources
See If You Qualify
Free · No obligation · About 2 minutes
Updated 13 sources
This may apply to you if
The process
You answer a few questions
About two minutes. Nothing is sent until you agree on the last step and press submit.
A lawyer looks at it
A lawyer at the firm reads your answers and checks them against the current case criteria.
The firm decides and gets in touch
If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.
At a glance
Who qualifies
These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.
Jimena Tatiana Hathaway · Harvard T.H. Chan School of Public Health; Massachusetts Eye and Ear, Harvard Medical School · Study author
Finding: The author abstract reports a semaglutide–NAION association in selected patients at one center; the observational design does not establish a causal link.
Hathaway et al., semaglutide and NAION, original author abstract and metadata (opens in a new tab) · Jul 3, 2024 · Checked Oct 3, 2026
Pharmacovigilance Risk Assessment Committee · European Medicines Agency · European medicines safety committee
Finding: The June 2025 review concluded NAION is a very rare side effect of semaglutide and recommended a product-information update.
EMA PRAC meeting highlights June2–5,2025, notice June6,2025 (opens in a new tab) · Jun 6, 2025 · Checked Oct 3, 2026
Karen Spencer Marston · United States District Court for the Eastern District of Pennsylvania · United States District Judge
Finding: The signed August 27 order schedules a master complaint and expert motions in MDL 3163; those procedural dates do not determine each person’s limitation period.
MDL3163 Case Management Order14, August27,2026 (opens in a new tab) · Aug 27, 2026 · Checked Oct 3, 2026
Massachusetts Eye and Ear, Harvard Medical School · JAMA Ophthalmology · 2024
Read the source: Semaglutide and NAION in patients at one neuro-ophthalmology service (opens in a new tab) · Checked Oct 3, 2026
European Medicines Agency · 2025
Read the source: PRAC semaglutide–NAION safety review (opens in a new tab) · Checked Oct 3, 2026
Not covered by this case
Check cost deductions and expenses owed without winning.
Source: ABA Model Rule1.5: Fees · as of Oct 3, 2026
Federal guidance allows reasonable copying and mailing charges with access exceptions.
Source: HHS your medical records · as of Oct 3, 2026
List the product, diagnosis and dates. Ask the provider about access to missing records.
Source: HHS your medical records · as of Oct 3, 2026
Ask how the study and court record apply to your facts and which law controls your time limit.
Source: SDNY filing-time FAQ · as of Oct 3, 2026
Confirm the firm and record recipient. Read the fee, cost and consent terms before signing.
Source: ABA Model Rule1.5: Fees · as of Oct 3, 2026
If you used a GLP-1 drug and have a confirmed NAION diagnosis, ask a lawyer to review your records. NAION is a form of optic nerve injury with a long name: nonarteritic anterior ischemic optic neuropathy. Sudden sight loss alone does not prove this diagnosis or the cause.
Start with the drug name in your pharmacy records and the diagnosis in your eye chart. Ask the firm which products and injuries it reviews. Do not select a diagnosis from a form before an eye specialist has assessed you. Court records discuss proof of use and proof of diagnosis, not a symptom-only promise of acceptance.
The July court order lists allegations involving Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro and Zepbound. That list describes the claims before the court. It does not mean that a study or regulator has found the same medical risk for every drug. Give the lawyer your exact product history rather than choosing a brand you recognize from an ad.
A caregiver can help prepare a record list with the patient’s permission. Ask the provider what authority is needed to obtain someone else’s chart. Note gaps in the history and dates you do not know. Do not fill them with an assumed cause or a diagnosis the clinician has not made.
The federal NAION cases share pretrial work as MDL 3163 in eastern Pennsylvania before Judge Karen S. Marston. A July order prioritizes shared questions about cause and drug warnings. The October 1, 2026 court report lists 247 pending actions, not people approved for payment.
MDL means that cases share pretrial work in one court. The transfer order groups the NAION allegations separately from the gastrointestinal injury cases in MDL 3094. The shared drug names do not make the two groups one lawsuit or give them one schedule. Ask which court record applies to your injury.
The July 2 order refers to 137 cases as of June 15, 2026. The later October report lists 247 pending actions. Each number has its own report date and scope. Neither count measures how many people will win, what their injuries are worth or how much a new claim may recover.
The August 27 scheduling order sets dates for a master complaint and later expert motions. These are steps for the court and parties. This page has not audited every later docket entry or verified a personal payment program. Ask for the latest order when a firm describes the current stage of your case.
Ask a lawyer what losses your records could support. A civil claim can seek relief for harm, but responsibility and damages need proof. The court and medical sources reviewed here do not provide a personal payout formula.
Keep eye care bills and notes about changes in daily tasks that you want the lawyer to assess. Ask which losses the law allows and how each would be documented. Separate known costs from future care you want to discuss. Do not treat a case count or study risk estimate as an award estimate.
If you are offered a settlement, ask which claim and parties it covers. Read the release and deductions before agreeing. The sources reviewed for this page do not establish the terms of such an offer. No minimum award, settlement range or payment date is supplied here.
Ask the firm to explain the fee, case expenses and any charge for a first discussion. Check what you could owe if the claim loses. The actual terms of a free review offer need checking before you rely on them.
The ABA model rule describes a signed written fee agreement when the lawyer’s fee depends on the outcome. It calls for the calculation method and expense terms. That includes expenses owed without winning. This model guidance does not establish a partner firm’s terms or your state’s adopted rule.
Ask who pays for charts, experts and other case work. Check when costs are deducted and whether that changes the lawyer’s share. Covered providers may charge reasonable copying and mailing costs for records. Ask which chart pages are needed before ordering a large set.
Ask a lawyer which law sets your filing time. The claim type and applicable law matter. A court management date is not everyone’s personal deadline to bring a claim.
The August 27 order sets October 28, 2026 for the master complaint in MDL 3163. It sets July 2, 2027 for certain expert and summary judgment motions. Those dates govern the specified court work. They do not promise that a person can wait until then to ask about an injury.
Prepare dates for drug use, first sight changes, diagnosis and any earlier claim or release. Mark an uncertain date as uncertain. Ask who will check your filing time and confirm whether a complaint has been filed for you. Sending an intake form is not the court filing that starts a federal civil case.
Seek eye care right away for sudden sight loss or rapid worsening. Do not wait for a lawsuit form to get medical help. Tell the clinician which medicines you use and what changed.
The European safety committee advises contacting a doctor without delay for these symptoms on semaglutide. Its notice says semaglutide should be stopped if NAION is confirmed. An eye assessment and the prescriber’s treatment plan matter; a claim advertisement cannot confirm the diagnosis or choose your drug plan.
After care is arranged, keep the eye reports, test results and medicine history you already have. Ask the provider how to obtain missing records. Write down dates you remember and label estimates as estimates. Do not alter a chart or guess which medicine caused the problem to fit an intake question.
Use the first discussion to identify the drug, eye diagnosis and relevant dates. Ask how the firm would assess cause and filing time. Check its identity, fees and record recipient before signing or sharing a chart.
First, list what you have and what is missing. A pharmacy history and an eye specialist’s findings answer different questions. Ask the lawyer which records are needed first. If another lawyer already handles the injury, discuss any new agreement with that lawyer.
Next, ask what remains to be proved in your case. The July order distinguishes whether a drug can cause an injury in general from whether it caused one person’s injury. A group proceeding does not decide those questions for every patient. Ask how the firm will assess your records against the medical evidence.
Before sharing records, confirm the recipient and the permission the request needs. Federal record-access guidance does not certify this site’s intake privacy or response speed. These operational terms remain unverified here. Ask what the next step is and whether the firm has agreed to represent you.
A 2024 study found an association between semaglutide use and NAION in selected patients at one eye-care center. It was based on existing records, not a randomized trial. It does not prove that the drug caused one person’s sight loss.
The author abstract describes a registry of 16,827 people without prior NAION. It reports a diabetes group of 710 and an overweight or obesity group of 979. Those are separate reported groups, not one total of treated or matched patients. The full paper was not reviewed for this package.
In June 2025, the European safety committee concluded that NAION is a very rare side effect of semaglutide. Its frequency category is up to 1 in 10,000. The notice names Ozempic, Rybelsus and Wegovy. This is a regulatory conclusion for semaglutide, not proof of the same risk for every drug named in the court claims.
The study and agency review answer different questions. The clinic study’s selected population does not give each user a personal chance of injury. A regulatory safety finding is also distinct from proving an individual legal claim. Ask the clinician about care and the lawyer about what proof your case needs.
The answers below address diagnosis, drug records, the semaglutide warning and the separate court groups. Use them to prepare a medical or legal discussion. They do not confirm a firm’s acceptance rules or replace an eye assessment.
The court orders support the case grouping and dated schedules. The study abstract and European agency notice support their limited medical summaries. Record-access and fee guidance support preparation questions. None supplies a personal award or this site’s intake terms.
Ask the lawyer which pharmacy and eye records are needed. Keep the actual product history, eye findings, and relevant dates; mark gaps rather than guess. Ask the provider about access and any copying costs.
Source: HHS: Your Medical Records · as of Oct 7, 2026
No symptom alone proves this diagnosis or the cause. EMA says patients on semaglutide who have sudden vision loss or rapidly worsening eyesight should contact their doctor without delay. Tell the clinician about your medicines and changes.
Source: EMA PRAC meeting highlights, June 2025 · as of Oct 7, 2026
It depends. The reviewed European notice addresses semaglutide and names Ozempic, Rybelsus, and Wegovy. It does not establish the same medical finding for every drug named in the NAION cases.
Source: EMA PRAC meeting highlights, June 2025 · as of Oct 7, 2026
The transfer order groups NAION vision-loss allegations in MDL 3163. The gastrointestinal claims are in the separate MDL 3094. Shared drug names do not give both groups one schedule or prove either claim. Ask the lawyer which proceeding applies to your diagnosis.
Source: JPML MDL3163 transfer order, December15,2025 · as of Oct 7, 2026
No, the October 28, 2026 master-complaint date is not everyone’s personal filing deadline. That date is a court management deadline in MDL 3163. Ask a lawyer to check your state law, dates, and any prior claim or release.
Source: MDL3163 Case Management Order14, August27,2026 · as of Oct 7, 2026
No, the MDL master-complaint date does not control every person's filing deadline. It is a court management date for the grouped case. A lawyer can check your state law, vision-loss date, and product history.
Source: MDL 3163 Case Management Order 14, August 27, 2026 · as of Oct 7, 2026
No, a semaglutide warning does not prove your individual NAION claim. It can be relevant background for certain products. Your diagnosis, timing, drug history, and other risk factors still need review.
Source: EMA PRAC meeting highlights, June 2025 · as of Oct 7, 2026
Checked against 13 primary sources by People's Justice editors · Updated
How we make moneyThe review is free and private. Asking for it doesn’t commit you to anything.
Register your interest